🇺🇸 FDA
Pipeline program

A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Pharmacological Effects of PT00114 in Healthy Volunteers

PT00114-001A

Phase 1 other active

Quick answer

A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Pharmacological Effects of PT00114 in Healthy Volunteers for Phase I study in healthy male and female volunteers. Intended indication: mood disorders is a Phase 1 program (other) at Protagenic Therapeutics, Inc.new with 1 ClinicalTrials.gov record(s).

Program details

Company
Protagenic Therapeutics, Inc.new
Indication
Phase I study in healthy male and female volunteers. Intended indication: mood disorders
Phase
Phase 1
Modality
other
Status
active

Clinical trials